[go: up one dir, main page]

ATE192931T1 - Morphogen-induzierte modulation von entzündlichen antworten - Google Patents

Morphogen-induzierte modulation von entzündlichen antworten

Info

Publication number
ATE192931T1
ATE192931T1 AT92919544T AT92919544T ATE192931T1 AT E192931 T1 ATE192931 T1 AT E192931T1 AT 92919544 T AT92919544 T AT 92919544T AT 92919544 T AT92919544 T AT 92919544T AT E192931 T1 ATE192931 T1 AT E192931T1
Authority
AT
Austria
Prior art keywords
morphogen
inflammatory responses
induced modulation
methods
tissue
Prior art date
Application number
AT92919544T
Other languages
English (en)
Inventor
Thangavel Kuberasampath
Roy H L Pang
Hermann Oppermann
David C Rueger
Charles M Cohen
Engin Ozkaynak
John E Smart
Original Assignee
Creative Biomolecules Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27419430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE192931(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Creative Biomolecules Inc filed Critical Creative Biomolecules Inc
Application granted granted Critical
Publication of ATE192931T1 publication Critical patent/ATE192931T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/625—Extraction from natural sources
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
AT92919544T 1991-08-30 1992-08-28 Morphogen-induzierte modulation von entzündlichen antworten ATE192931T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75286191A 1991-08-30 1991-08-30
US75305991A 1991-08-30 1991-08-30
US75276491A 1991-08-30 1991-08-30
PCT/US1992/007358 WO1993004692A1 (en) 1991-08-30 1992-08-28 Morphogen-induced modulation of inflammatory response

Publications (1)

Publication Number Publication Date
ATE192931T1 true ATE192931T1 (de) 2000-06-15

Family

ID=27419430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92919544T ATE192931T1 (de) 1991-08-30 1992-08-28 Morphogen-induzierte modulation von entzündlichen antworten

Country Status (8)

Country Link
EP (1) EP0601106B2 (de)
JP (1) JP3693338B2 (de)
AT (1) ATE192931T1 (de)
AU (1) AU669127B2 (de)
CA (1) CA2116562C (de)
DE (1) DE69231062T3 (de)
ES (1) ES2149776T5 (de)
WO (1) WO1993004692A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US7378392B1 (en) 1990-05-16 2008-05-27 Genetics Institute, Llc Bone and cartilage inductive proteins
US5688678A (en) * 1990-05-16 1997-11-18 Genetics Institute, Inc. DNA encoding and methods for producing BMP-8 proteins
US5972884A (en) * 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
CA2363965C (en) 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US5739107A (en) * 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US6287816B1 (en) * 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
WO1993000432A1 (en) * 1991-06-25 1993-01-07 Genetics Institute, Inc. Bmp-9 compositions
AU5129293A (en) * 1992-09-15 1994-04-12 Creative Biomolecules, Inc. 60a protein-induced morphogenesis
JP4255986B2 (ja) * 1992-09-15 2009-04-22 ストライカー・コーポレーション 消化管潰瘍のモルフォゲン治療
AU719153B2 (en) * 1992-09-15 2000-05-04 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
DK0661987T3 (da) * 1992-09-16 1998-09-14 Creative Biomolecules Inc Morphogeninduceret leverregeneration
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
JP4847634B2 (ja) * 1996-03-22 2011-12-28 ストライカー・コーポレーション 中枢神経系の虚血または外傷の機能的回復を増大させる方法
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US6034062A (en) * 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
WO1998050060A1 (en) * 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies for acute renal failure
WO1998054572A1 (en) 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
WO2001028602A1 (en) 1999-10-15 2001-04-26 Genetics Institute, Inc. Formulations of hyaluronic acid for delivery of osteogenic proteins
WO2002099037A2 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
EP1298434A1 (de) * 2001-10-01 2003-04-02 Cognis France S.A. Verfahren zum Auffinden neuer Wirkstoffe mit androgen-ähnlichen Eigenschaften
JP4473576B2 (ja) 2001-11-19 2010-06-02 スキール テヒノロギー ゲーエムベーハー 骨誘導性および骨伝導特性を有するデバイス
DK1572950T3 (da) 2002-06-17 2013-02-04 Thrasos Inc Enkeltdomæne TDF-relaterede forbindelser og analoger deraf
DE60304584T2 (de) 2002-09-10 2007-04-26 Scil Technology Gmbh Unter verringerter sauerstoffkonzentration mit einem osteoinduktiven protein beschichtetes metallimplantat
CA2558395C (en) 2004-03-10 2011-11-29 Scil Technology Gmbh Coated implants, their manufacturing and use thereof
US8410246B2 (en) 2004-06-17 2013-04-02 Thrasos, Inc. TDF-related compounds and analogs thereof
JP2009508532A (ja) 2005-09-20 2009-03-05 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
US20080020014A1 (en) * 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
AU2009214629A1 (en) 2008-02-13 2009-08-20 Eric T. Choi BMP-7 for use in treating vascular sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269408A3 (de) * 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
EP1225225A3 (de) * 1988-04-08 2003-01-08 Stryker Corporation Osteogene Vorrichtungen
AU4056089A (en) * 1988-07-20 1990-02-19 Amgen, Inc. Method of treating inflammatory disorders by reducing phagocyte activation
WO1991005802A1 (en) * 1989-10-17 1991-05-02 Creative Biomolecules, Inc. Osteogenic devices
ES2120964T3 (es) * 1990-10-18 1998-11-16 Stryker Corp Peptidos osteogenicos.
ATE203166T1 (de) * 1991-03-11 2001-08-15 Curis Inc Protein-induzierende morphogenese

Also Published As

Publication number Publication date
JP3693338B2 (ja) 2005-09-07
DE69231062T3 (de) 2004-07-29
EP0601106B2 (de) 2003-11-05
WO1993004692A1 (en) 1993-03-18
CA2116562C (en) 1999-04-13
CA2116562A1 (en) 1993-03-18
AU2564592A (en) 1993-04-05
AU669127B2 (en) 1996-05-30
EP0601106B1 (de) 2000-05-17
ES2149776T5 (es) 2004-07-01
ES2149776T3 (es) 2000-11-16
DE69231062T2 (de) 2001-02-15
DE69231062D1 (de) 2000-06-21
EP0601106A1 (de) 1994-06-15
JPH06510989A (ja) 1994-12-08

Similar Documents

Publication Publication Date Title
ATE192931T1 (de) Morphogen-induzierte modulation von entzündlichen antworten
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
NO951432L (no) Farmasöytiske preparater
ATE148632T1 (de) Synergistische therapeutische zusammensetzungen und verfahren
FI944549L (fi) Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
ES2120948T3 (es) Procedimiento y composiciones que mejoran los sintomas de la sepsis.
DE69434223D1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DK0744957T3 (da) Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A
DK390585D0 (da) Kontrastmiddel og fremgangsmaade til anvendelse heraf
IT8319306A0 (it) Composizione di antralina oppure di uno dei suoi derivati in un estere aromatico e suo impiego nel trattamento di malattie della pelle e delle unghie.
FI941699L (fi) Atsabisyklo-aryyliasetyleeni- ja arylenyynioksiimit kolinenergisina aineina ja hoitomenetelmät
NO894222D0 (no) Fremgangsmaater for behandling av profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer til anvendelse i nevnte metoder.
IT8367917A0 (it) Forno combinato con un inceneritore di fumi per il trattamento di prodotti quali tessuti in pezza e procedimento per la sua utilizzazione
DK0579488T3 (da) Præparat til behandling af mastitis og matritis
DE69328730D1 (de) Vorbeugung von verletzungen und degenerationen von photorezeptoren durch neurotrophische faktoren
TW263437B (de)
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
NO921223D0 (no) Kombinasjonspreparat med antitrombotisk virkning
NO933056L (no) Anordning og fremgangsmaate for aa gjenvinne slamsirkulasjon ved broennoperasjoner
FI924215A0 (fi) Anvaendningen av il-4 foer oekning av immunreaktionen foerorsakad infektiosa antigen aemnen.
ATE64094T1 (de) Neue kombinationspraeparate mit antidepressiver wirkung.
ES541944A0 (es) Procedimiento para preparar liposomas que contiene alergenoso fracciones de alergenos inhalables
DE69306559D1 (de) Neue kardioprotektive wirkstoffe
SE8900564D0 (sv) Novel medicinal use
ATE70440T1 (de) Verwendung von anipamil als artereosklerosemittel.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0601106

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee